Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
Spravato was already available in the market before today's FDA approval and has already proven to be a financial success for ...
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...